(Q42595787)

English

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

scientific article published on 28 August 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

multiple sclerosis

0 references

Carolyn A. Young

10

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

object named as

G Pardo

6

0 references

Olga L. Barbarash

object named as

O Barbarash

2

0 references

author name string

G Giovannoni

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

F Casset-Semanaz

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

J King

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

L Metz

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

J Simsarian

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

P S Sørensen

8

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

B Stubinski

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

publication date

28 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

219-228

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

The immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Immunogenicity of recombinant human proteins: causes and consequences

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Multiple sclerosis: side effects of interferon beta therapy and their management

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508097299

21 January 2018

Identifiers

10.1177/1352458508097299

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42595787&oldid=1962479674"